Sign In
Buy MGNX
$4.69
+0.110 (+2.40%)
At Close: Jun 23, 2026
MacroGenics, Inc. (MGNX) Q3 2023 Earnings Call Transcript
12:20am, Tuesday, 07'th Nov 2023
MacroGenics, Inc. (MGNX) Q3 2023 Earnings Call Transcript
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Nov 2023
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based ther
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
04:30pm, Tuesday, 31'st Oct 2023
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therap
MacroGenics to Participate in Upcoming Investor Conferences
04:30pm, Thursday, 31'st Aug 2023
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therap
3 Under-the-Radar Biotech Stocks to Buy in 2023
07:40am, Saturday, 19'th Aug 2023
Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a part of a combination therapy.
MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why
12:24pm, Monday, 14'th Aug 2023
MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.
Why Shares of MacroGenics Are Jumping Thursday
12:33pm, Thursday, 10'th Aug 2023
MacroGenics saw a big jump in net income. It receives royalties from Sanofi for breast cancer drug Tzield.
MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript
09:21pm, Wednesday, 09'th Aug 2023
MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jim Karrels - VP and CFO Scott Koenig - President and CEO Conference Call Participants
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
05:35pm, Monday, 31'st Jul 2023
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-b
MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)
02:47am, Monday, 29'th May 2023
MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growth for the company, with doubled revenue and a narr
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
07:07pm, Tuesday, 09'th May 2023
MacroGenics (MGNX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $1.07. This compares to loss of $1.08 per share a year ago.
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
04:30pm, Thursday, 04'th May 2023
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic
MacroGenics to Participate in Upcoming Investor Conferences
06:15pm, Monday, 24'th Apr 2023
ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the
Why MacroGenics Stock Inched Higher on Monday
06:59pm, Monday, 20'th Mar 2023
Two analysts raised their price targets on the cancer-focused biotech. They are the latest prognosticators to adjust their takes on the company following its latest earnings release.
Why MacroGenics Stock Tumbled Today
10:15pm, Friday, 17'th Mar 2023 The Motley Fool
The company had quite a comedown shortly after releasing its latest set of annual results.
